MedTrace Logo

Memantine in Body Focused Repetitive Behaviors

NCT04792645 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.

Conditions

  • Trichotillomania (Hair-Pulling Disorder)
  • Dermatillomania

Interventions

DRUG

Placebo

Pill that contains no medicine

DRUG

Memantine

Cognition-enhancing medication

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jon Grant, JD, MD, MPH · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2022-07-08
Completion
2022-07-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04792645 on ClinicalTrials.gov